Cargando…
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129
Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought an...
Ejemplares similares
-
Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129
por: Badimon, Lina, et al.
Publicado: (2021) -
A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease
por: Robinson, Emma Louise, et al.
Publicado: (2020) -
Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129
por: Vanhaverbeke, Maarten, et al.
Publicado: (2021) -
Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium
por: de Gonzalo-Calvo, David, et al.
Publicado: (2022) -
What Actually Works for Activity Recognition in Scenarios with Significant Domain Shift: Lessons Learned from the 2019 and 2020 Sussex-Huawei Challenges †
por: Kalabakov, Stefan, et al.
Publicado: (2022)